BridgeBio Pharma, Inc. (Nasdaq: BBIO), a company focused on genetic diseases, and Eidos Therapeutics, Inc. (Nasdaq: EIDX), a company focused on transthyretin (TTR) amyloidosis (ATTR), today announced they have entered into a definitive agreement under which BridgeBio has agreed to acquire all of the outstanding common stock of Eidos it does not already own, representing approximately 36.3% of Eidos’ outstanding shares. Eidos stockholders will have the right to receive in the transaction, at their election, either 1.85 shares of BridgeBio common stock or $73.26 in cash per Eidos share in the transaction, up to an aggregate maximum of $175 million of cash.
Read the full article: BridgeBio Pharma Acquires Rest of Eidos Therapeutics //
Source: https://www.globenewswire.com/news-release/2020/10/05/2103406/0/en/BridgeBio-Pharma-and-Eidos-Therapeutics-Announce-Merger-Agreement.html